【Heron Biotech】Application for Phase II Clinical Trial of B10 L-BPA Injection for Triple-Negative Breast Cancer

1. Date of occurrence: May 25, 2026. 2. Drug name: B10 L-BPA Injection. 3. Purpose: To evaluate the efficacy and safety of Boron Neutron Capture Therapy (BNCT) for recurrent locally advanced or metastatic triple-negative breast cancer. 4. Development stage: Phase II clinical trial. 5. Current status: IND application submitted to TFDA. Accumulated R&D expenses are not disclosed to protect investor interests. 6. Next steps: Subject to TFDA review progress. 7. Market status: Triple-negative breast cancer is a challenging indication; successful application of BNCT could create new growth opportunities. 8. Other: This is an academic clinical trial primarily for research purposes. 9. Risk: Drug development is long and costly with no guarantee of success.